Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
See detailPharmacological evaluation of BM-573, a dual thromboxane A(2) receptor antagonist and thromboxane synthase inhibitor, as potential anti-metastatic agent
de Leval, X. J.; Dassesse, T.; Benoit, V. et al

in Blood (2003, November 16), 102(11, Part 2), 72

Detailed reference viewed: 11 (4 ULg)
Peer Reviewed
See detailPharmacological evaluation of BM-573, a dual thromboxane A2 receptor antagonist and thromboxane synthase inhibitor, as potential anti-metastatic agent
De Leval, X.; Dassesse, T.; Benoît, V. et al

Poster (2003, December)

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailPharmacological evaluation of cromakalim analogues: towards the discovery of new inhibitors of insulin secretion from rat pancreatic Beta-cells
Sebille, S.; becker, B.; Antoine, M. H. et al

in Fundamental & Clinical Pharmacology (2002)

Detailed reference viewed: 6 (3 ULg)
Full Text
Peer Reviewed
See detailPharmacological evaluation of cromakalim analogues: towards the discovery of new inhibitors of insulin secretion from rat pancreatic Beta-cells
Sebille, S.; Becker, B.; Antoine, M. H. et al

in Fundamental & Clinical Pharmacology (2002)

Detailed reference viewed: 5 (1 ULg)
Peer Reviewed
See detailPharmacological evaluation of cromakalim analogues: towards the discovery of new inhibitors of insulin secretion from rat pancreatic β-cells
Sebille, S.; Becker, B.; Antoine, M. H. et al

Poster (2002, March 02)

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailPharmacological evaluation of cromakalim analogues: towards the discovery of new inhibitors of insulin secretion from rat pancreatic -cells
Sebille, S.; Becker, B.; Antoine, M. H. et al

in Fundamental & Clinical Pharmacology (2002)

Detailed reference viewed: 3 (0 ULg)
Peer Reviewed
See detailPharmacological evaluation of original sulfonylureas as thromboxane A2 antagonists
Dogne, J. M.; De Leval, X.; Neven, P. et al

Poster (2000, March 04)

See detailPharmacological evaluation of original sulfonylureas as thromboxane A2 antagonists
Dogne, J.-M.; De Leval, X.; Neven, P. et al

in Fundamental & Clinical Pharmacology (2000), 14

Detailed reference viewed: 2 (0 ULg)
Full Text
Peer Reviewed
See detailPharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function
Dogné, Jean-Michel ULg; De Leval, X.; Kolh, Philippe ULg et al

in Prostaglandins, Leukotrienes, and Essential Fatty Acids (2003)

Detailed reference viewed: 17 (6 ULg)
Full Text
Peer Reviewed
See detailPharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function
Dogne, J. M.; de Leval, X.; Kolh, Philippe ULg et al

in Prostaglandins, Leukotrienes, and Essential Fatty Acids (2003), 68(1), 49-54

The aim of this work was to evaluate the effects of BM-567 ( N-pentyl-N'-[(2-cyclohexylamino-5-nitrobenzene)sulfonyl]urea), a torasemide derivative. on both thromboxane A(2) (TXA(2)) receptors (TP) and ... [more ▼]

The aim of this work was to evaluate the effects of BM-567 ( N-pentyl-N'-[(2-cyclohexylamino-5-nitrobenzene)sulfonyl]urea), a torasemide derivative. on both thromboxane A(2) (TXA(2)) receptors (TP) and thromboxane synthase of human platelets. The drug affinity for TP receptors of human washed platelets has been determined. In this test BM-567 showed a high affinity (IC50: 1.1+/-0.1 nM) for the TP receptors in comparison with BM-531 (IC50: 7.8+/-0.7 nM) and sulotroban (IC50: 931+/-85 nM), two TXA(2) antagonists. We also demonstrated that BM-567 prevented platelet aggregation induced by arachidonic acid (AA) (600 muM) (ED100: 0.20+/-0.10muM), U-46619, a stable TXA(2) agonist (1 muM) (ED50: 0.30+/-0.04 muM) and collagen (1 mug ml(-1)) (% of inhibition: 44.3+/-4.3% at 10 muM) and inhibited the second wave of ADP (2 muM). Moreover, when BM-567 was incubated in whole blood from healthy donors, the closure time measured by the Platelet Function analyzer (PFA-100) was significantly prolonged (closure time: 215+/-21 s) by using collagen/epinephrine cartridges. Finally, at the concentration of 1 muM, BM-567 completely reduced the TXB2 production from human platelets stimulated with AA (600 muM). These results indicate that BM-567 is a novel combined TXA(2) receptor antagonist and thromboxane synthase inhibitor characterized by a powerful antiplatelet potency. (C) 2002 Elsevier Science Ltd. All rights reserved. [less ▲]

Detailed reference viewed: 26 (4 ULg)
Full Text
Peer Reviewed
See detailPharmacological evaluation of the novel thromboxane modulator BM-567 (II/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation
De Leval, X.; Benoit, V.; Delarge, J. et al

in Prostaglandins, Leukotrienes, and Essential Fatty Acids (2003)

Detailed reference viewed: 10 (2 ULg)
Peer Reviewed
See detailPharmacological evaluation of the thromboxane A2 receptor antagonist BM-613
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

Poster (2003, May)

Detailed reference viewed: 2 (0 ULg)
Peer Reviewed
See detailPharmacological evaluation of TP receptor antagonists by differential activity on alpha and beta isoforms
Hanson, Julien ULg; Dogne, J. M.; Ghiotto, J. et al

Poster (2006, November 18)

Detailed reference viewed: 1 (0 ULg)
Full Text
Peer Reviewed
See detailPharmacological management : osteoporosis and osteoarthritis, similarities and differences
Reginster, Jean-Yves ULg

in Osteoporosis International (2013), 24(1), 75-76

Detailed reference viewed: 3 (2 ULg)
Full Text
Peer Reviewed
See detailPharmacological Modulation of the Bystander Effect in the Herpes Simplex Virus Thymidine Kinase/Ganciclovir Gene Therapy System: Effects of Dibutyryl Adenosine 3',5'-Cyclic Monophosphate, Alpha-Glycyrrhetinic Acid, and Cytosine Arabinoside
Robe, Pierre ULg; Princen, Frédéric; Martin, Didier ULg et al

in Biochemical Pharmacology (2000), 60(2), 241-9

The herpes simplex virus type 1 thymidine kinase (HSV1-tk) suicide gene/ganciclovir system was first applied to the treatment of glioblastoma tumors, but was hampered by the low gene transfection yield ... [more ▼]

The herpes simplex virus type 1 thymidine kinase (HSV1-tk) suicide gene/ganciclovir system was first applied to the treatment of glioblastoma tumors, but was hampered by the low gene transfection yield. Fortunately, the gap junction-dependent diffusion of phosphorylated ganciclovir metabolites from transfected cells to their neighbors proved to enhance the overall benefit of this strategy. However, as tumor cells are often gap junction-deficient, we sought to restore this property pharmacologically and hence to improve the efficacy of the treatment. We demonstrated that this approach was feasible in glioblastoma cells using dibutyryl adenosine 3',5'-cyclic monophosphate (cAMP) (100 microM) as a pharmacological inducer of gap junctions. alpha-Glycyrrhetinic acid (25 microM), on the other hand, strongly inhibited both gap junction-mediated intercellular communication and the bystander effect, thus confirming the role of gap junctions in HSV-tk-mediated bystander killing. Using cytosine arabinoside as a growth inhibitor, we underlined the role of tumor cell proliferation in the sensitivity of HSV-tk-transfected cells to ganciclovir and demonstrated its correlation with the importance of the bystander effect. [less ▲]

Detailed reference viewed: 62 (13 ULg)
Full Text
See detailPharmacological prevention of type 2 diabetes.
Scheen, André ULg

in The Epidemiology of Diabetes Mellitus (2008)

Detailed reference viewed: 11 (2 ULg)